Showing 1179 results
- https://www.novartis.com/news/media-releases/novartis-presents-new-five-year-data-disability-outcomes-and-safety-kesimpta-ofatumumab-people-living-relapsing-multiple-sclerosisThe ALITHIOS open-label extension study showed continuous treatment with Kesimpta® (ofatumumab) for up to five years in relapsing multiple sclerosis (RMS) patients was associated with reduced risk of…
- https://www.novartis.com/news/media-releases/novartis-delivers-strong-sales-growth-robust-margin-expansion-and-major-innovation-milestones-raises-fy-guidanceAd hoc announcement pursuant to Art. 53 LR Q1 sales grew +8% (cc1, +3% USD) and core operating income grew +15% (cc, +8% USD) Innovative Medicines (IM) sales grew +7% (cc, +3% USD) and core…
- https://www.novartis.com/news/media-releases/novartis-realise-une-croissance-forte-de-son-chiffre-daffaires-une-expansion-robuste-de-sa-marge-des-etapes-majeures-de-linnovation-et-rehausse-ses-previsions-pour-lexercice-2023Annonce événementielle au sens de l’art. 53 RC Au T1, chiffre d’affaires en hausse de +8% (tcc1, +3% USD) et du résultat opérationnel de +15% (tcc, +8% USD) Innovative Medicines (IM): hausse de +…
- https://www.novartis.com/news/media-releases/novartis-erzielt-kraftige-umsatzsteigerungen-eine-robuste-margenerhohung-und-wichtige-innovationsmeilensteine-erhohung-der-jahresprognoseAd-hoc-Mitteilung gemäss Art. 53 KR Der Umsatz wuchs im ersten Quartal um +8% (kWk1, +3% USD), und das operative Kernergebnis verbesserte sich um +15% (kWk, +8% USD) Innovative…
- https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministrationLes actionnaires approuvent la 18e hausse consécutive du dividende, à CHF 2,60 par action (+6 %) au titre de l'exercice 2014. De même que d'autres administrateurs qui étaient candidats à leur…
- https://www.novartis.com/news/media-releases/aktionare-genehmigen-alle-antrage-des-verwaltungsrats-von-novartisAktionäre genehmigen für 2014 die 18. Dividendenerhöhung in Folge auf CHF 2,60 pro Aktie (+6%) Dr. Jörg Reinhardt als Präsident des Novartis Verwaltungsrats sowie alle weiteren Mitglieder des…
- https://www.novartis.com/news/media-releases/novartis-lung-cancer-drug-zykadia-recommended-eu-approval-patients-alk-nsclc-previously-treated-crizotinibIf approved, Zykadia (ceritinib) would be the first treatment option for patients in Europe with ALK+ NSCLC previously treated with crizotinib ALK+ NSCLC is driven by a rearrangement of the…
- https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-farydak-first-hdac-inhibitor-patients-multiple-myelomaFarydak, an HDAC inhibitor with epigenetic activity, approved in combination for patients who received at least two prior regimens including bortezomib and IMiD[1] Farydak prolonged median…
- https://www.novartis.com/news/media-releases/novartis-heart-failure-medicine-lcz696-granted-fda-priority-reviewDecision could speed access to LCZ696 for HFrEF patients in the US, reducing total review time from 12 to 8 months Filing is based on results from the landmark PARADIGM-HF study[1] …
- https://www.novartis.com/news/media-releases/alcon-receives-fda-approval-pazeotm-solution-ocular-allergy-itch-reliefUS Food and Drug Administration grants approval of Pazeo(TM) (olopatadine hydrochloride ophthalmic solution) 0.7% for sale in the United States Developed with efficacy data at 24 hours, post dose…
Pagination
- ‹ Previous page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- …
- 118
- › Next page